《山东大学学报(理学版)》 ›› 2025, Vol. 60 ›› Issue (9): 10-23.doi: 10.6040/j.issn.1671-9352.0.2025.069
• • 上一篇
宁书怡,戴召媛,冯心池*
NING Shuyi, DAI Zhaoyuan, FENG Xinchi*
摘要: 基于超高效液相色谱-四极杆-静电场轨道阱高分辨质谱(UPLC-QE-Orbitrap-MS)技术鉴定龙血竭中的化学成分,并建立同时测定龙血竭中主要成分含量的分析方法。采用色谱柱为ACQUITY UPLC BEH C18(1.7 μm, 2.1×100 mm),含0.1%甲酸的乙腈-水为流动相,高能电喷雾离子源(HESI),负离子模式扫描。结合各化合物的精确分子质量、二级质谱碎片信息和文献报道数据及对照品比对,鉴定龙血竭中的化学成分。建立基于UPLC-QE-Orbitrap-MS技术同时测定龙血竭中龙血素A、龙血素B、龙血素C、龙血素D、白藜芦醇和7,4'-二羟基黄酮质量分数的分析方法。定量分析方法以0.1%甲酸水(A)与0.1%甲酸乙腈(B)为流动相。梯度洗脱程序:0~2 min, 22%~45%B; 2~6 min, 45%B; 6~7 min, 45%~95%B; 7~8 min, 95%~22%B; 8~11 min, 22%B。流速为0.25 mL/min;柱温为35 ℃;进样量为5 μL。HESI源,负离子模式下平行反应监测(parallel reaction monitoring, PRM)扫描,毛细管温度为350 ℃,喷雾电压为2.8 kV,S-透镜水平为35 kV,鞘气流速为35 arb,辅助气流速为10 arb。结果表明,在龙血竭药材中,鉴定出25个化合物,其中黄酮类化合物22个,二苯乙烯类化合物3个,共9个化合物经与对照品比对而准确鉴定。选择龙血素A、龙血素B、龙血素C、龙血素D、白藜芦醇和7,4'-二羟基黄酮为质量分数测定的指标成分,6个成分在各自的质量浓度范围内线性关系良好(r≥0.999 2),精密度、重复性、稳定性均符合相关要求,加样回收率为92.2%~105.0%。对14批龙血竭药材进行质量分数测定,方法可行。龙血素B在龙血竭中的质量分数为0.41%~7.25%,是6个指标成分中质量分数最高的化学物质。综上,本研究在龙血竭化学成分系统分析的基础上,建立6种主要成分的质量分数测定方法,为龙血竭的药效物质基础与质量控制提供参考。
中图分类号:
[1] 杨敏,杨瑞,覃彬华,等. 民族药龙血竭研究进展[J]. 海峡药学,2019,31(11):49-52. YANG Min, YANG Rui, QIN Binhua, et al. Research progress of dragons blood, a national medicine [J]. Strait Pharmaceutical Journal, 2019, 31(11):49-52. [2] 徐红英,张晓燕. 中药血竭研究进展[J]. 中医药学报,2011,39(4):101-103. XU Hongying, ZHANG Xiaoyan. Research progress of dragons blood[J]. Acta Chinese Medicine and Pharmacology, 2011, 39(4):101-103. [3] FAN J Y, YI T, SZE-TO C M, et al. A systematic review of the botanical, phytochemical and pharmacological profile of Dracaena cochinchinensis, a plant source of the ethnomedicine “dragons blood” [J]. Molecules, 2014,19(7):10650-10669. [4] 孙晶,庞道然,郑姣,等. 龙血竭的药理、临床及质量控制研究进展[J]. 中国医院用药评价与分析,2017,17(11):1445-1447. SUN Jing, PANG Daoran, ZHENG Jiao, et al. Research progress in pharmacology, clinic and quality control of dragons blood[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2017, 17(11):1445-1447. [5] 国家药典委员会. 中华人民共和国药典:一部[M]. 北京:中国医药科技出版社,2020. Chinese Pharmacopoeia Commission. Pharmacopoeia of the Peoples Republic of China: part I [M]. Beijing: China Medical Science and Technology Press, 2020. [6] 林忆龙,文亦磊,黄洪,等. 龙血竭化学成分及药理作用研究进展[J]. 中国民族民间医药,2020,29(6):50-55. LIN Yilong, WEN Yilei, HUANG Hong, et al. Research progress on chemical constituents and pharmacological effects of dragons blood[J]. Chinese Journal of Ethnomedicine and Ethnopharmacy, 2020, 29(6):50-55. [7] 王建壮,吕华冲. 比色法测定龙血竭总黄酮含量[J]. 中国实验方剂学杂志,2013,19(16):55-58. WANG Jianzhuang, LV Huachong. content determination of total flavonoids in Resina Draconis by colorimetric method[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2013, 19(16):55-58. [8] 李竣,朱功俊,陈素,等. HPLC法同时测定不同产地龙血竭中3种黄酮类成分[J]. 中南民族大学学报(自然科学版),2017,36(2):45-48. LI Jun, ZHU Gongjun, CHEN Su, et al. Simultaneous determination of three kinds of flavonoids in Resina Draconis from different regions by HPLC[J]. Journal of South-Central University for Nationalities(Natural Science Edition), 2017, 36(2):45-48. [9] 李云,萧伟,秦建平,等. HPLC测定龙血竭提取物中龙血素A, B和7,4'-二羟基黄酮的含量[J]. 中国实验方剂学杂志, 2012, 18(3):45-47. LI Yun, XIAO Wei, QIN Jianping, et al. Determination of loureirin A, B and 7,4'-dihydroxy flavone in extract of Resina Draconis by HPLC[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2012, 18(3):45-47. [10] 张静泽,胡迎庆,郭鹏. 紫外分光光度法测定龙血竭中二氢查耳酮的含量[J]. 中成药,2004,26(6):77-79. ZHANG Jingze, HU Yingqing, GUO Peng. Determination of dihydrochalcone in dragons blood by ultraviolet spectrophotometry[J]. Chinese Traditional Patent Medicine, 2004, 26(6):77-79. [11] WANG S, LI Y W, ZHANG N X, et al. Screening of ESR2-targeted anti-postmenopausal osteoporosis chemistry from Rehmanniae Radix Preparata based on affinity ultrafiltration with UPLC-QE-Orbitrap-MS[J]. Journal of Chromatography B, 2025, 1251:124419. [12] ZHANG K Y, LI C N, ZHANG N X, et al. UPLC-QE-orbitrap-based cell metabolomics and network pharmacology to reveal the mechanism of N-benzylhexadecanamide isolated from maca(Lepidium meyenii walp.)against testicular dysfunction[J]. Molecules, 2023, 28(10):4064. [13] 李涛,谭璐,徐文泱,等. UPLC-Q/Orbitrap MS法检测水产品中12种抗生素残留[J]. 食品工业,2020,41(5):300-303. LI Tao, TAN Lu, XU Wenyang, et al. Determination of 12 kinds of antibiotics in aquatic products by UPLC-Q/orbitrap MS[J]. The Food Industry, 2020, 41(5):300-303. [14] 汤钜添,陈少茹,张诚光. 基于UPLC-QE-Orbitrap-MS技术鉴定中药三棱入血成分[J]. 深圳中西医结合杂志,2024,34(5):72-74. TANG Jutian, CHEN Shaoru, ZHANG Chengguang. Identification of blood components of rhizoma sparganii based on UPLC-QE-orbitrap-MS technology[J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2024, 34(5):72-74. [15] 国家药典委员会. 中华人民共和国药典:四部[M]. 北京:中国医药科技出版社,2020. Chinese Pharmacopoeia Commission. Pharmacopoeia of the Peoples Republic of China: part IV[M]. Beijing: China Medical Science and Technology Press, 2020. [16] JIANG Y, ZHANG G P, YAN D, et al. Bioactivity-guided fractionation of the traditional Chinese medicine Resina Draconis reveals loureirin B as a PAI-1 inhibitor[J]. Evidence-Based Complementary and Alternative Medicine, 2017, 2017:9425963. [17] BAI X Z, HE T, LIU J Q, et al. Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scarvia TGF-β/Smad pathway[J]. Experimental Dermatology, 2015, 24(5):355-360. [18] HU J P, ZHANG R, TANG M, et al. Loureirin B inhibits the proliferation of hepatic stellate cells and the Wnt/β-catenin signaling pathway by regulating miR-148-3p[J]. Cellular & Molecular Biology Letters, 2018, 23:35. [19] LI R, JIA H Y, SI M, et al. Loureirin B protects against cerebral ischemia/reperfusion injury through modulating M1/M2 microglial polarization via STAT6/NF-kappaB signaling pathway[J]. European Journal of Pharmacology, 2023, 953:175860. [20] FANG H W, DING Y T, XIA S J, et al. Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways[J]. European Journal of Pharmacology, 2022, 936:175377. [21] SHI S J, ZHAO Q R, KE C H, et al. Loureirin B exerts its immunosuppressive effects by inhibiting STIM1/Orai1 and KV1.3 channels[J]. Frontiers in Pharmacology, 2021, 12:685092. [22] 杨波,郭建恩,韩俊婷,等. 龙血素A对大鼠局灶性脑缺血再灌注引起的脑损伤及机制探讨[J]. 中药新药与临床药理,2010,21(2):103-107. YANG Bo, GUO Jianen, HAN Junting, et al. Effect of loureirin A on focal cerebral ischemia-reperfusion rats and its mechanism[J]. Traditional Chinese Drug Research & Clinical Pharmacology, 2010, 21(2):103-107. [23] LIU Y S, MI Y, WANG Y P, et al. Loureirin C inhibits ferroptosis after cerebral ischemia reperfusion through regulation of the Nrf2 pathway in mice[J]. Phytomedicine, 2023, 113:154729. [24] SU X Q, SONG Y L, ZHANG J, et al. Dihydrochalcones and homoisoflavanes from the red resin of Dracaena cochinchinensis(Chinese dragonsblood)[J]. Fitoterapia, 2014, 99:64-71. [25] CHENG L, JIN Z X, ZHAO R, et al. Resveratrol attenuates inflammation and oxidative stress induced by myocardial ischemia-reperfusion injury: role of Nrf2/ARE pathway[J]. International Journal of Clinical and Experimental Medicine, 2015, 8(7):10420-10428. [26] JIANG M, SU X, LIU J L, et al. Systems pharmacology-dissection of the molecular mechanisms of dragons blood in improving ischemic stroke prognosis[J]. Evidence-Based Complementary and Alternative Medicine, 2020, 2020:4858201. [27] 朱智德,吴玉强. 剑叶龙血树繁育种植技术与人工诱导机制研究综述[J]. 大众科技,2015,17(12):99-101. ZHU Zhide, WU Yuqiang. The research summarizes of D.cochinchinensis about breeding cultivation technology and artificial induction mechanism[J]. Popular Science & Technology, 2015, 17(12):99-101. |
[1] | 桂梁,徐遥,何世柱,张元哲,刘康,赵军. 基于动态邻居选择的知识图谱事实错误检测方法[J]. 《山东大学学报(理学版)》, 2024, 59(7): 76-84. |
[2] | 陆玮洁1 ,刘冰1,2 ,邹华彬1 ,张衡1 ,张新玲1 ,杨国生1 . 茶叶HNMR指纹图谱双指标序列分析[J]. J4, 2009, 44(3): 35-38 . |
|